This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Blum, J. L. Search for Related Content PubMed PubMed Citation Articles by Blum, J. L.

The Role of Capecitabine, an Oral, Enzymatically Activated Fluoropyrimidine, in the Treatment of Metastatic Breast Cancer

U.S. Oncology and Baylor-Charles A. Sammons Cancer Center, Dallas, Texas, USA

Correspondence: Joanne L. Blum, M.D., Ph.D., U.S. Oncology, 3535 Worth Street, Suite 600, Dallas, Texas 75246, USA. Telephone: 214-370-1000; Fax: 214-370-1060; e-mail: Joanne.Blum{at}usoncology.com

Capecitabine is an oral fluoropyrimidine that mimics continuous infusion 5-fluorouracil and generates 5-fluorouracil preferentially at the tumor site. It is activated via a three-step enzymatic pathway, the final step of which requires thymidine phosphorylase, an enzyme that is significantly more active in tumor than normal tissue. As an oral agent, capecitabine is more convenient for patients and medical personnel, and avoids the complications associated with venous access. This paper reviews the development and clinical experience of capecitabine in breast cancer treatment. Clinical trials have established the efficacy and tolerability of capecitabine in anthracycline- and taxane-pretreated metastatic breast cancer, showing that capecitabine is an effective therapy for patients who have exhausted all established treatment options. Moreover, randomized, phase II studies have demonstrated that capecitabine is effective in anthracycline-pretreated patients and as first-line therapy for metastatic breast cancer. In addition to its confirmed efficacy, the favorable safety profile of capecitabine, particularly the low myelosuppression rate, makes it an attractive agent for incorporation into combination regimens. Therefore numerous trials have assessed the feasibility of capecitabine-containing regimens, and have shown promising results. Capecitabine is an important new treatment option for breast cancer patients, and ongoing clinical trials should further define its role in a range of settings.

Key Words. Capecitabine • Oral fluoropyrimidine • Thymidine phosphorylase • Breast cancer • Colorectal cancer • Taxane-resistant • Docetaxel • Paclitaxel

This article has been cited by other articles:

				R. Bartsch, C. Wenzel, G. Altorjai, U. Pluschnig, M. Rudas, R. M. Mader, M. Gnant, C. C. Zielinski, and G. G. Steger Capecitabine and Trastuzumab in Heavily Pretreated Metastatic Breast Cancer J. Clin. Oncol., September 1, 2007; 25(25): 3853 - 3858. [Abstract] [Full Text] [PDF]

				Q. Li, M. P. Kozar, T. W. Shearer, L. H. Xie, A. J. Lin, K. S. Smith, Y. Si, L. Anova, J. Zhang, W. K. Milhous, et al. Pharmacokinetics, Safety, and Hydrolysis of Oral Pyrroloquinazolinediamines Administered in Single and Multiple Doses in Rats Antimicrob. Agents Chemother., August 1, 2007; 51(8): 2898 - 2904. [Abstract] [Full Text] [PDF]

				J. L. Blum, E. C. Dees, A. Chacko, L. Doane, S. Ethirajan, J. Hopkins, R. McMahon, S. Merten, A. Negron, M. Neubauer, et al. Phase II Trial of Capecitabine and Weekly Paclitaxel As First-Line Therapy for Metastatic Breast Cancer J. Clin. Oncol., September 20, 2006; 24(27): 4384 - 4390. [Abstract] [Full Text] [PDF]

				T. A. Rich, R. C. Shepard, and S. T. Mosley Four Decades of Continuing Innovation With Fluorouracil: Current and Future Approaches to Fluorouracil Chemoradiation Therapy J. Clin. Oncol., June 1, 2004; 22(11): 2214 - 2232. [Abstract] [Full Text] [PDF]

				M. Malet-Martino and R. Martino Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capecitabine, UFT, S-1): A Review Oncologist, August 1, 2002; 7(4): 288 - 323. [Abstract] [Full Text] [PDF]

				M. Venturini, L. Del Mastro, O. Garrone, C. Angiolini, M. Merlano, M. Bergaglio, G. Tolino, A. Lambiase, A. Baldini, G. Canavese, et al. Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer Ann. Onc., April 1, 2002; 13(4): 546 - 552. [Abstract] [Full Text] [PDF]